Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Lymphoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × penpulimab × Clear all
NCT06825494 2025-12-18

Clinical Studies for the Treatment of Advanced Solid Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
194 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡